245 related articles for article (PubMed ID: 12061944)
41. Can selection of rapidly progressing patients shorten clinical trials in amyotrophic lateral sclerosis?
de Carvalho M; Swash M
Arch Neurol; 2006 Apr; 63(4):557-60. PubMed ID: 16606769
[TBL] [Abstract][Full Text] [Related]
42. Clinical features that distinguish PLS, upper motor neuron-dominant ALS, and typical ALS.
Gordon PH; Cheng B; Katz IB; Mitsumoto H; Rowland LP
Neurology; 2009 Jun; 72(22):1948-52. PubMed ID: 19487653
[TBL] [Abstract][Full Text] [Related]
43. What has changed with riluzole?
Meininger V; Lacomblez L; Salachas F
J Neurol; 2000 Dec; 247():19-22. PubMed ID: 11200701
[TBL] [Abstract][Full Text] [Related]
44. An association study of riluzole serum concentration and survival and disease progression in patients with ALS.
Groeneveld GJ; van Kan HJ; Lie-A-Huen L; Guchelaar HJ; van den Berg LH
Clin Pharmacol Ther; 2008 May; 83(5):718-22. PubMed ID: 17898704
[TBL] [Abstract][Full Text] [Related]
45. Clinical trials in ALS: what did we learn from recent trials in humans?
Meininger V
Neurodegener Dis; 2005; 2(3-4):208-14. PubMed ID: 16909027
[TBL] [Abstract][Full Text] [Related]
46. Long-term safety of riluzole in amyotrophic lateral sclerosis.
Lacomblez L; Bensimon G; Leigh PN; Debove C; Bejuit R; Truffinet P; Meininger V;
Amyotroph Lateral Scler Other Motor Neuron Disord; 2002 Mar; 3(1):23-9. PubMed ID: 12061945
[TBL] [Abstract][Full Text] [Related]
47. What has changed with riluzole?
Meininger V; Lacomblez L; Salachas F
J Neurol; 2000 Dec; 247 Suppl 6():VI/19-22. PubMed ID: 19714404
[TBL] [Abstract][Full Text] [Related]
48. Pentoxifylline in ALS: a double-blind, randomized, multicenter, placebo-controlled trial.
Meininger V; Asselain B; Guillet P; Leigh PN; Ludolph A; Lacomblez L; Robberecht W;
Neurology; 2006 Jan; 66(1):88-92. PubMed ID: 16401852
[TBL] [Abstract][Full Text] [Related]
49. Survival of 793 patients with amyotrophic lateral sclerosis diagnosed over a 28-year period.
Testa D; Lovati R; Ferrarini M; Salmoiraghi F; Filippini G
Amyotroph Lateral Scler Other Motor Neuron Disord; 2004 Dec; 5(4):208-12. PubMed ID: 15799548
[TBL] [Abstract][Full Text] [Related]
50. Malnutrition at the time of diagnosis is associated with a shorter disease duration in ALS.
Limousin N; Blasco H; Corcia P; Gordon PH; De Toffol B; Andres C; Praline J
J Neurol Sci; 2010 Oct; 297(1-2):36-9. PubMed ID: 20673675
[TBL] [Abstract][Full Text] [Related]
51. Predictability of disease progression in amyotrophic lateral sclerosis.
Czaplinski A; Yen AA; Simpson EP; Appel SH
Muscle Nerve; 2006 Dec; 34(6):702-8. PubMed ID: 16967489
[TBL] [Abstract][Full Text] [Related]
52. Clinical phenotypes and natural progression for motor neuron disease: analysis from an Australian database.
Talman P; Forbes A; Mathers S
Amyotroph Lateral Scler; 2009 Apr; 10(2):79-84. PubMed ID: 18608095
[TBL] [Abstract][Full Text] [Related]
53. Survival of patients with amyotrophic lateral sclerosis in a population-based registry.
Millul A; Beghi E; Logroscino G; Micheli A; Vitelli E; Zardi A
Neuroepidemiology; 2005; 25(3):114-9. PubMed ID: 15956808
[TBL] [Abstract][Full Text] [Related]
54. Prognostic factors for early severity in a childhood multiple sclerosis cohort.
Mikaeloff Y; Caridade G; Assi S; Suissa S; Tardieu M
Pediatrics; 2006 Sep; 118(3):1133-9. PubMed ID: 16951008
[TBL] [Abstract][Full Text] [Related]
55. Disease progression and survival in ALS: first multi-state model approach.
Gil J; Preux PM; Alioum A; Ketzoian C; Desport JC; Druet-Cabanac M; Couratier P
Amyotroph Lateral Scler; 2007 Aug; 8(4):224-9. PubMed ID: 17653920
[TBL] [Abstract][Full Text] [Related]
56. Defining survival as an outcome measure in amyotrophic lateral sclerosis.
Gordon PH; Corcia P; Lacomblez L; Pochigaeva K; Abitbol JL; Cudkowicz M; Leigh PN; Meininger V
Arch Neurol; 2009 Jun; 66(6):758-61. PubMed ID: 19506136
[TBL] [Abstract][Full Text] [Related]
57. Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials.
Meininger V; Bensimon G; Bradley WR; Brooks B; Douillet P; Eisen AA; Lacomblez L; Leigh PN; Robberecht W
Amyotroph Lateral Scler Other Motor Neuron Disord; 2004 Jun; 5(2):107-17. PubMed ID: 15204012
[TBL] [Abstract][Full Text] [Related]
58. [Epidemiological and clinical aspects of amyotrophic lateral sclerosis in neurological clinic of Dakar].
Sene DF; Ndiaye M; Toure K; Ndao AK; Thiam A; Diop AG; Ndiaye IP
Dakar Med; 2004; 49(3):167-71. PubMed ID: 15776613
[TBL] [Abstract][Full Text] [Related]
59. The natural history of primary lateral sclerosis.
Gordon PH; Cheng B; Katz IB; Pinto M; Hays AP; Mitsumoto H; Rowland LP
Neurology; 2006 Mar; 66(5):647-53. PubMed ID: 16534101
[TBL] [Abstract][Full Text] [Related]
60. [Cotreatment of amyotrophic lateral sclerosis patients].
Iwasaki Y; Ikeda K
Rinsho Shinkeigaku; 1999 Dec; 39(12):1253-5. PubMed ID: 10791091
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
